Molecular Devices Secures U.S. Patent for Scalable, Standardized Organoid Culture Method
Patent strengthens 3D Ready™ portfolio, enabling consistent, assay-ready organoids for predictive drug discovery
SAN JOSE, Calif., Nov. 13, 2025 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, today announced the issuance of U.S. Patent No. 12,351,820 B2, titled “Methods for Culturing Organoids.” The patent covers aspects of the company’s novel bioreactor-based method for producing organoids. Molecular Devices’ method results in organoids with unprecedented consistency and scale, enhancing the company’s 3D Ready™ portfolio, which offers assay-ready, cryopreserved patient-derived organoids for immediate use in research or expansion services of a customer’s own organoid line.
The company’s bioprocess technology standardizes organoid development by controlling cell cluster size and culture environment. This approach improves organoid uniformity and scalability, providing researchers with reliable models for drug screening, disease modeling, and toxicology testing.
“This patent marks an important step toward industrializing organoid research,” said Mary Duseau, President of Molecular Devices. “By transforming what was once an academic process into a scalable, quality-controlled workflow, we’re helping biopharma organizations accelerate discovery while aligning with the FDA’s guidance to adopt more human-relevant, new approach methodologies (NAMs). Our goal is to give scientists confidence in consistent, assay-ready models that truly reflect patient biology.”
Key advantages of Molecular Devices’ process include:
- Controlled bioreactor workflow: Produces organoids in large batches under tightly controlled culture conditions, reducing reliance on manual culture methods.
- Standardized and reproducible: Minimizes variability by producing organoids with defined size, ensuring organoid batches perform consistently across assays and labs.
- Versatile research applications: Supports high-throughput screening, disease modeling, and toxicity testing, enabling more predictive, human-relevant studies.
With this patent, Molecular Devices deepens its leadership in next-generation 3D biology and strengthens its IP portfolio to drive broader adoption of organoid systems in academic, biotech, and pharmaceutical research. Together with its integrated imaging, automation, and data analytics platforms, the company is empowering scientists to streamline discovery in precision medicine, regenerative biology, and early-stage drug development.
Find additional patent details here.
About Molecular Devices, LLC.
Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe. For more information, please visit www.moleculardevices.com.
Molecular Devices is proud to be a part of Danaher, a global science and technology leader. Together, we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health. For more information, please visit www.danaher.com.
Media Contact:
Amy Smith
Molecular Devices
Corporate Communications Manager
Mobile: 1.408.334.4699
Email: amy.smith@moldev.com